Stockscreener 앱 받기
2.48
0.00%
0.00
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - ForexTV.com
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - Marketscreener.com
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - StockTitan
Comprehensive Analysis of Growth Drivers and Challenges in the Neurological Biomarkers Market In New Report - WhaTech
ABOSAcumen Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com Australia
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com South Africa
Acumen extends Alzheimer's drug partnership with Lonza - Investing.com India
Acumen extends Alzheimer's drug partnership with Lonza - Investing.com
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com Canada
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease - The Manila Times
Acumen extends collaboration with Lonza - TipRanks
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for - EIN News
Acumen Health Holdings to Acquire Avenova Brand Enhancing Eye Health Portfolio - MSN
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 - StockTitan
Acumen Health Holdings to Acquire Avenova Brand Enhancing Eye Health Portfolio - MyChesCo
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - StockTitan
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Yahoo Finance
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Drop in Short Interest - MarketBeat
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - Quantisnow
Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 9.9% - MarketBeat
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan
Perhaps timely catching Acumen Pharmaceuticals Inc (ABOS) would be a good idea - SETE News
Acumen Pharmaceuticals Inc (ABOS) stock: A year of ups and downs - US Post News
ABOS’s Market Whiplash: -28.65% YTD Decline, -15.17% Plunge in 30 Days - The InvestChronicle
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360% - Inkl
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Eledon Pharmaceuticals Inc (ELDN-Q) QuotePress Release - The Globe and Mail
Vanguard Group Inc. Sells 174,494 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
HC Wainwright Comments on Acumen Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ABOS) - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - Defense World
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Grows By 12.7% - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives “Buy” Rating from HC Wainwright - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) PT Lowered to $6.00 - MarketBeat
BTIG maintains Buy rating on Acumen stock amid trial progress By Investing.com - Investing.com Australia
Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Earnings Results, Misses Expectations By $0.06 EPS - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results - MarketBeat
BTIG maintains Buy rating on Acumen stock amid trial progress - Investing.com India
BTIG maintains Buy rating on Acumen stock amid trial progress - Investing.com
BTIG maintains Buy rating on Acumen stock amid trial progress By Investing.com - Investing.com UK
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives Buy Rating from HC Wainwright - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress By Investing.com - Investing.com Australia
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress - Investing.com
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress - Investing.com India
Earnings call: Acumen Pharmaceuticals reports on Q2 2024 progress By Investing.com - Investing.com UK
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 - InvestorPlace
Acumen Pharmaceuticals Unveils Updated Corporate Presentation and Financials - TipRanks
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights - StockTitan
Acumen Pharmaceuticals (ABOS) Set to Announce Earnings on Tuesday - Defense World
Acumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on Tuesday - MarketBeat
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024 - StockTitan
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet? - Simply Wall St
Price T Rowe Associates Inc. MD Takes Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Price T Rowe Associates Inc. MD Invests $4.45 Million in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
SG Americas Securities LLC Purchases Shares of 12,856 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Market Update: Acumen Pharmaceuticals Inc (ABOS) Sees Negative Movement, Closing at 3.29 - The Dwinnex
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's - Seeking Alpha
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 - WICZ
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease - StockTitan
Acumen Pharmaceuticals Presents Patient Experience and Biomarker - WICZ
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024 - ForexTV.com
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD ... - Enid News & Eagle
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024 - StockTitan
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded by Citigroup to Strong-Buy - MarketBeat
0.05%
4.86%
자본화:
|
볼륨(24시간):